These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
284 related articles for article (PubMed ID: 22919717)
1. [Research progress of sodium-glucose co-transporter 2 inhibitors for treatment of type 2 diabetes]. Wan HX; Shen JK Yao Xue Xue Bao; 2012 Jun; 47(6):716-24. PubMed ID: 22919717 [TBL] [Abstract][Full Text] [Related]
2. Synthetic strategy and SAR studies of C-glucoside heteroaryls as SGLT2 inhibitor: A review. Haider K; Pathak A; Rohilla A; Haider MR; Ahmad K; Yar MS Eur J Med Chem; 2019 Dec; 184():111773. PubMed ID: 31630053 [TBL] [Abstract][Full Text] [Related]
4. Design of SGLT2 Inhibitors for the Treatment of Type 2 Diabetes: A History Driven by Biology to Chemistry. Cai W; Jiang L; Xie Y; Liu Y; Liu W; Zhao G Med Chem; 2015; 11(4):317-28. PubMed ID: 25557661 [TBL] [Abstract][Full Text] [Related]
5. Recent Developments in Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors as a Valuable Tool in the Treatment of Type 2 Diabetes Mellitus. Kumar S; Khatik GL; Mittal A Mini Rev Med Chem; 2020; 20(3):170-182. PubMed ID: 32134370 [TBL] [Abstract][Full Text] [Related]
7. Identification of an oxime-containing C-glucosylarene as a potential inhibitor of sodium-dependent glucose co-transporter 2. Yuan MC; Yeh TK; Chen CT; Song JS; Huang YC; Hsieh TC; Huang CY; Huang YL; Wang MH; Wu SH; Yao CH; Chao YS; Lee JC Eur J Med Chem; 2018 Jan; 143():611-620. PubMed ID: 29216560 [TBL] [Abstract][Full Text] [Related]
8. Efficient synthesis of Empagliflozin, an inhibitor of SGLT-2, utilizing an AlCl3-promoted silane reduction of a β-glycopyranoside. Wang XJ; Zhang L; Byrne D; Nummy L; Weber D; Krishnamurthy D; Yee N; Senanayake CH Org Lett; 2014 Aug; 16(16):4090-3. PubMed ID: 25061799 [TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and biological evaluation of 6-deoxy O-spiroketal C-arylglucosides as novel renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes. Wang Y; Lou Y; Wang J; Li D; Chen H; Zheng T; Xia C; Song X; Dong T; Li J; Li J; Liu H Eur J Med Chem; 2019 Oct; 180():398-416. PubMed ID: 31325786 [TBL] [Abstract][Full Text] [Related]
10. C-aryl glucosides substituted at the 4'-position as potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes. Xu B; Feng Y; Cheng H; Song Y; Lv B; Wu Y; Wang C; Li S; Xu M; Du J; Peng K; Dong J; Zhang W; Zhang T; Zhu L; Ding H; Sheng Z; Welihinda A; Roberge JY; Seed B; Chen Y Bioorg Med Chem Lett; 2011 Aug; 21(15):4465-70. PubMed ID: 21737266 [TBL] [Abstract][Full Text] [Related]
11. Novel thiophenyl C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents. Lee SH; Song KS; Kim JY; Kang M; Lee JS; Cho SH; Park HJ; Kim J; Lee J Bioorg Med Chem; 2011 Oct; 19(19):5813-32. PubMed ID: 21906953 [TBL] [Abstract][Full Text] [Related]
12. Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug. Idris I; Donnelly R Diabetes Obes Metab; 2009 Feb; 11(2):79-88. PubMed ID: 19125776 [TBL] [Abstract][Full Text] [Related]
13. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. Meng W; Ellsworth BA; Nirschl AA; McCann PJ; Patel M; Girotra RN; Wu G; Sher PM; Morrison EP; Biller SA; Zahler R; Deshpande PP; Pullockaran A; Hagan DL; Morgan N; Taylor JR; Obermeier MT; Humphreys WG; Khanna A; Discenza L; Robertson JG; Wang A; Han S; Wetterau JR; Janovitz EB; Flint OP; Whaley JM; Washburn WN J Med Chem; 2008 Mar; 51(5):1145-9. PubMed ID: 18260618 [TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological evaluation of novel C-aryl d-glucofuranosides as sodium-dependent glucose co-transporter 2 inhibitors. Lin TS; Liw YW; Song JS; Hsieh TC; Yeh HW; Hsu LC; Lin CJ; Wu SH; Liang PH Bioorg Med Chem; 2013 Nov; 21(21):6282-91. PubMed ID: 24071445 [TBL] [Abstract][Full Text] [Related]
15. SGLT-2 Inhibitors: The Next-generation Treatment for Type 2 Diabetes Mellitus. Lukic N; Macvanin MT; Gluvic Z; Rizzo M; Radak D; Suri JS; Isenovic ER Curr Med Chem; 2024; 31(30):4781-4806. PubMed ID: 37855338 [TBL] [Abstract][Full Text] [Related]
16. [Dapagliflozin: Beyond glycemic control in the treatment of type 2 diabetes mellitus]. Sanz-Serra P; Pedro-Botet J; Flores-Le Roux JA; Benaiges D; Chillarón JJ Clin Investig Arterioscler; 2015; 27(4):205-11. PubMed ID: 25648671 [TBL] [Abstract][Full Text] [Related]
17. Type 2 Diabetes, SGLT2 Inhibitors, and Glucose Secretion. Hattersley AT; Thorens B N Engl J Med; 2015 Sep; 373(10):974-6. PubMed ID: 26332554 [No Abstract] [Full Text] [Related]